Cipla's subsidiary, InvaGen Pharmaceuticals Inc., has received final approval for its Abbreviated New Drug Application (ANDA) for Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Genzyme’s Renvela Tablets, 800 mg.
Renvela Tablets had US sales of approximately USD 1.85 billion for the 12-month period ending August 2017, according to IMS Health. Sevelamer Carbonate Tablets, 800 mg is a AB-rated generic equivalent to the reference listed drug (RLD), Renvela Tablets, 800 mg of Genzyme Corporation and are indicated for the control of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis.
Shares of the company gained Rs 10.1, or 1.65%, to trade at Rs 622.50. The total volume of shares traded was 130,385 at the BSE (9.48 a.m., Friday).